ORGOVYX: payments to doctors
Payments that named ORGOVYX as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $7.5M
- Providers
- 19,691
- Transactions
- 156,504
- Average per transaction
- $48
The per-transaction average — $48 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 19,691 providers the average total is $379, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Sumitomo Pharma America, Inc. | $2,727,800 | 36.5% |
| Pfizer | $2,517,597 | 33.7% |
| Myovant Sciences Inc. | $2,194,594 | 29.4% |
| PBG Puerto RICO LLC | $21,117 | 0.3% |
| Myovant Sciences GmbH | $6,662 | 0.1% |
| Array Biopharma Inc | $583 | 0.0% |
| Medivation Services LLC | $495 | 0.0% |